Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer - Wikidata - wikimedia - TriplyDB

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

http://www.wikidata.org/entity/Q24242243

about

Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance.Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review.

P2860

Q24234729-798AADF7-6F4D-4CD1-A098-15C9EF61CAFE Q33380411-D5974E63-08B5-4CB7-A74F-80B9999AEB59 Q36619756-9A97A693-334F-473E-BD44-1501BF9497EA Q36734996-648AEFF5-EF63-4116-BCDC-9D710DB8BFD7

P2860

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

http://www.wikidata.org/entity/Q24242243

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Anticoagulation for the initia ...... bolism in patients with cancer

@ast

Anticoagulation for the initia ...... bolism in patients with cancer

@en

Anticoagulation for the initia ...... bolism in patients with cancer

@en-gb

Anticoagulation for the initia ...... bolism in patients with cancer

@nl

type

label

Anticoagulation for the initia ...... bolism in patients with cancer

@ast

Anticoagulation for the initia ...... bolism in patients with cancer

@en

Anticoagulation for the initia ...... bolism in patients with cancer

@en-gb

Anticoagulation for the initia ...... bolism in patients with cancer

@nl

prefLabel

Anticoagulation for the initia ...... bolism in patients with cancer

@ast

Anticoagulation for the initia ...... bolism in patients with cancer

@en

Anticoagulation for the initia ...... bolism in patients with cancer

@en-gb

Anticoagulation for the initia ...... bolism in patients with cancer

@nl

P1433

Q24242243-1BCF11A5-6D56-4DE7-8D2D-1DF465D0930C

P1476

Q24242243-57C4ECF6-DF06-465E-B2E0-C10B6C38465B

P2093

Q24242243-9E86E847-3D0E-43A1-8E22-962E97128D89

Q24242243-A875D83C-0841-4457-B40F-B2AF0533D750

P2860

Q24242243-01E13A08-89A7-4123-AA40-485DC4DD976D

Q24242243-0290966E-5230-4664-A2FF-D92AF3546BC8

Q24242243-0E10A762-77FC-4C71-A4AF-2CEB25A064FC

Q24242243-0F1AE581-7F69-44CF-B1FE-A38CC15F7BA2

Q24242243-0F9CE6F1-B8B9-41E6-974A-CF3704E177BD

Q24242243-100D3D5A-DFB5-4D28-901D-969B94DC9E0A

Q24242243-147CF5FD-9339-40BE-B060-666DA832ABBF

Q24242243-20EAD99B-D41F-4E7B-A4F5-D469EA57DAD6

Q24242243-21344469-1B7F-4304-A99D-0202021D0761

Q24242243-29ECB1DA-DAEF-4638-89E3-FAD6DED6C4D5

P31

Q24242243-BD7F1BBD-0E9D-41B1-B2BE-28AA30AB6181

Q24242243-d115c641-c289-489d-a5e7-770c569c72a8

P356

Q24242243-0279008F-FF8A-4B8E-8FCF-8E150629BB6D

P50

Q24242243-5F808437-D5A7-4425-B847-2B00977973E3

Q24242243-87B46D7C-F17D-452F-AC3B-9176B912A379

Q24242243-88E9DE7B-8040-4E68-A59A-4152B1D66533

Q24242243-E4E4122F-FC26-4160-B53E-8227B1611437

Q24242243-EC3F3B2F-1FAE-460F-8769-F2E920B90698

P577

Q24242243-15A21D16-8BF6-4299-9C1D-D355C6A667DA

P698

Q24242243-C29620BD-E5BB-4879-9368-CB2FFD9EDF71

P921

Q24242243-76936EF8-B326-4D43-AF59-1E04AA5829CD

P356

14651858.CD006649.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Anticoagulation for the initia ...... bolism in patients with cancer

@en

P2093

Paola Muti

http://www.w3.org/2001/XMLSchema#string

Sandeep Rohilla

http://www.w3.org/2001/XMLSchema#string

P2860

Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation

Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

Measuring inconsistency in meta-analyses

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis.

Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.

P31

scholarly article

P356

10.1002/14651858.CD006649.PUB2

http://www.w3.org/2001/XMLSchema#string

P50

Holger Schünemann

Maddalena Barba

Francesca Sperati

Irene Terrenato

P577

2008-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18254108

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation